TrialInvestigational new drugs2014

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Jeeyun Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.